Refractory heartburn: Comparison of intercellular space diameter in documented GERD vs. Functional heartburn

American Journal of Gastroenterology

Volumn 106, Issue 5, 2011, Pages 844-850

  Vela, Marcelo F ^a,c   Craft, Brandon M ^a   Sharma, Neeraj ^a   Freeman, Janice ^a   Hazen Martin, Debra ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS BIOPSY; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; HUMAN TISSUE; INTERCELLULAR SPACE; MALE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; TRANSMISSION ELECTRON MICROSCOPY;

ADULT; DIAGNOSIS, DIFFERENTIAL; ENDOSCOPY, GASTROINTESTINAL; EPITHELIUM; ESOPHAGEAL PH MONITORING; ESOPHAGOSCOPY; ESOPHAGUS; EXTRACELLULAR SPACE; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; MONITORING, AMBULATORY; PROTON PUMP INHIBITORS;

EID: 79955636199     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.476     Document Type: Article

References (25)

1. Locke GR III, Talley NJ, Fett SL et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-1456. (Pubitemid 27181367)
2. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009; 58: 295-309.
3. Fass R, Murthy U, Hayden CW et al. Omeperazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14: 1595-603. (Pubitemid 32011733)
4. Richter JE. The patient with refractory gastroesophageal reflux disease. Dis Esophagus 2006; 19: 443-7. (Pubitemid 44644679)
5. Pandolfino JE, Vela MF. Technical review: esophageal reflux monitoring. Gastrointest Endosc 2009; 69: 917-930.
6. Galmiche JP, Clouse RE, Balint A et al. Functional esophageal disorders. Gastroenterology 2006; 130: 1459-1465.
7. Orlando RC, Powell DW, Carney CN. Pathophysiology of acute acid injury in rabbit esophageal epithelium. J Clin Invest 1981; 68: 286-293. (Pubitemid 11048101)
8. Tobey NA, Carson JL, Alkiek RA et al. Dilated intercellular spaces: a morphological feature of acid reflux-damaged human esophageal epithelium. Gastroenterology 1996; 111: 1200-1205. (Pubitemid 26362244)
9. Calabrese C, Fabbri A, Bortolotti M et al. Dilated intercellular spaces as a marker of esophageal damage: comparative results in gastroesophageal reflux disease with or without bile reflux. Aliment Pharmacol Ther 2003; 18: 525-532. (Pubitemid 37152293)
10. Calabrese C, Bortolotti M, Fabbri A et al. Reversibility of GERD ultrastructural alterations and relief of symptoms aft er omeprazole treatment. Am J Gastroenterol 2005; 100: 537-542. (Pubitemid 40487549)
11. Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1995; 90: 1804-1807.
12. Sing S, Richter JE, Bradley LA et al. The symptom index. Differential usefulness in suspected acid-related complaints of heartburn and chest pain. Dig Dis Sci 1993; 38: 1402-1408. (Pubitemid 23266617)
13. Johnson LF, DeMeester TR. Twenty-four hour pH monitoring of the distal esophagus. Am J Gastroenterol 1974; 62: 323-332.
14. Vela MF, Camacho-Lobato L, Srinivasan R et al. Intraesophageal impedance and pH measurement of acid and nonacid reflux: effect of omeprazole. Gastroenterology 2001; 120: 1599-606. (Pubitemid 32523479)
15. Lundell LR, Dent J, Bennet JR et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-180. (Pubitemid 29333764)
16. Caviglia R, Ribolsi M, Maggiano N et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological acid exposure. Am J Gastroenterol 2005; 100: 543-8. (Pubitemid 40487550)
17. Dickman R, Fass R. Functional heartburn. Curr Treat Options Gastroenterol 2005; 8: 285-291. (Pubitemid 41223400)
18. Jones H, Cooper P, Miller V et al. Treatment of noncardiac chest pain: a controlled trial of hypnotherapy. Gut 2006; 55: 1403-1408. (Pubitemid 44476782)
19. Vela MF, Tutuian R, Katz PO et al. Baclofen reduces both acid and nonacid gastroesophageal reflux: a study using combined multichannel intraluminal impedance and pH (MII/pH). Aliment Pharmacol Ther 2003; 17: 243-251. (Pubitemid 36174255)
20. Farre R, Cardozo L, Blondeau K et al. Esophageal mucosal damage induced by weakly acidic solutions containing unconjugated bile acids, similar to reflux in GERD patients " on " PPI, can be prevented with anti-oxidants [abstr]. Gastroenterology 2009; 136 (Suppl 1): A16.
21. Farre R, van Malenstein H, De Vos R et al. Short exposure of esophageal mucosa to bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and provoke dilated intercellular spaces. Gut 2008; 57: 1366-1374.
22. Farre R, Fornari F, Blondeau K et al. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human esophagus. Gut 2010; 59: 164-9.
23. Connor J, Richter JE. Increasing yield also increases false positives and best serves to exclude GERD. Am J Gastroenterol 2006; 101: 460-3. (Pubitemid 43340919)
24. van Malenstein H, FarréR, Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol 2008; 103: 1021-1028. (Pubitemid 351501085)
25. Farre R, De Vos R, Geboes K et al. Critical role of stress in increased esophageal mucosa permeability and dilated intercellular spaces. Gut 2007; 56: 1191-1197. (Pubitemid 47300417)